SCHEMBL233701

SCHEMBL233701

C#CCCC(N)=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9720 0.86
SCHEMBL15124812 0.83
SCHEMBL4231630 0.81 CYP1A2 (0.67)
SCHEMBL15124720 0.81 CYP1A2 (0.67)
SCHEMBL4235132 0.81 CYP1A2 (0.67)
SCHEMBL30836939 0.81 CYP1A2 (0.67)
SCHEMBL27988568 0.81 CYP1A2 (0.67)
SCHEMBL18425215 0.79 CYP1A2 (0.37)
Carbamic Acid SCHEMBL16013788 0.75 ACHE (0.47)
Acetamide SCHEMBL7200814 0.73 LMNA (0.50)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 197 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4727648-A1 CANNABINOID RECEPTOR 2 MODULATORS F. Hoffmann-La Roche AG (CH) 2026-04-22 EP claimed
EP-3917907-B1 MODULATORS OF POTASSIUM ION CHANNELS AND USES THEREOF UNIV DEGLI STUDI DI SALERNO (IT) 2025-05-21 EP claimed
WO-2024256505-A1 CANNABINOID RECEPTOR 2 MODULATORS F. HOFFMANN-LA ROCHE AG (CH) 2024-12-19 WO claimed
US-20240239759-A1 ISOXAZOLINE COMPOSITIONS AND THEIR USE AS ANTIPARASITICS INTERVET INC. (US) 2024-07-18 US claimed
US-11358935-B2 Prodrugs of lanicemine and their method of use BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. (US) 2022-06-14 US claimed
US-20210061775-A1 ISOXAZOLINE COMPOSITIONS AND THEIR USE AS ANTIPARASITICS INTERVET INC. (US) 2021-03-04 US claimed
US-20180155301-A1 ISOXAZOLINE COMPOSITIONS AND THEIR USE AS ANTIPARASITICS INTERVET INC. (US) 2018-06-07 US claimed
US-20160332975-A1 ISOXAZOLINE COMPOSITIONS AND THEIR USE AS ANTIPARASITICS INTERVET INC. (US) 2016-11-17 US claimed
US-20160237037-A1 INHIBITORS OF HISTONE DEMETHYLASES GILEAD SCIENCES, INC. 2016-08-18 US claimed
EP-2545777-A1 Isoxazoline compositions and their use as antiparasitics Intervet International B.V. (NL) 2013-01-16 EP claimed
US-20110059988-A1 ISOXAZOLINE COMPOSITIONS AND THEIR USE AS ANTIPARASITICS INTERVET INTERNATIONAL B.V. 2011-03-10 US claimed
EP-2190289-A2 ISOXAZOLINE COMPOSITIONS AND THEIR USE AS ANTIPARASITICS Intervet International B.V. (NL) 2010-06-02 EP claimed
WO-2009024541-A2 ISOXAZOLINE COMPOSITIONS AND THEIR USE AS ANTIPARASITICS INTERVET INTERNATIONAL B.V. (NL) 2009-02-26 WO claimed
CN-115850338-B Bisaziridine-containing nucleoside compound and preparation method and application thereof XI'AN JIAOTONG UNIVERSITY (CN) 2026-05-26 CN disclosed
EP-4727648-A1 CANNABINOID RECEPTOR 2 MODULATORS F. Hoffmann-La Roche AG (CH) 2026-04-22 EP disclosed
CN-112261954-B Compounds having affinity substances for antibodies and bio-orthogonalization functional groups or salts thereof 味之素株式会社 2025-06-24 CN disclosed
EP-0765879-A1 13-Substituted milbemycin 5-oxime derivatives, their preparation and their use against insects and other pests SANKYO COMPANY LIMITED (JP) 1997-04-02 EP disclosed
WO-1996029309-A1 N-ACYLPIPERIDINYLCARBONYLAMINOCARBOXYLIC ACIDS AND THEIR USE AS GLYCOPROTEIN IIB/IIa ANTAGONISTS AND FIBRINOGEN-BLOOD PLATELETS BINDING INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1996-09-26 WO disclosed
EP-0669912-A1 N-(3-PIPERIDINYLCARBONYL)-BETA-ALANINE DERIVATIVES AS PAF ANTAGONISTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1995-09-06 EP disclosed
WO-1995008536-A1 N-(3-PIPERIDINYLCARBONYL)-BETA-ALANINE DERIVATIVES AS PAF ANTAGONISTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1995-03-30 WO disclosed